← All trials
NCT06320353
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Jan 31, 2026
- First posted
- Mar 20, 2024
- Last posted
- Mar 20, 2024
- Enrollment
- 266
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- R-PharmLead sponsor
- Data Management 365 LLCCollaborator
- Government of RussiaCollaborator
- Exacte Labs LLCCollaborator
- R-PharmOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.